Randomised, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Mirabegron 25 mg and 50 mg Once-daily in Overactive Bladder (OAB)

van Kerrebroeck P1, Barkin J2, Castro-Diaz D3, Espuña-Pons M4, Frankel J5, Gousse A6, Martin N7, Stolzel M8, Gunther A8, Herschorn S9

Abstract Category

Detrusor Overactivity

Abstract 359
Non Discussion Poster
Scientific Non Discussion Poster Session 31
1. Maastricht University Medical Center, Maastricht, the Netherlands, 2. The Male Health Centre, Toronto, Ontario, Canada, 3. Hospital Universitario de Canarias, Tenerife, Spain, 4. Hospital Clinic I Provincial, Barcelona, Spain, 5. Seattle Urology Research Center, Burien, WA, USA, 6. Herbert Wertheim College of Medicine, Miramar, FL, USA, 7. Astellas Scientific and Medical Affairs, Inc., Deerfield, Illinois, 8. Astellas Pharma Europe, Leiderdorp, the Netherlands, 9. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada